Navigation Links
Millennium Laboratories Expands Pharmacogenetic Test to Help Clinicians Prescribe the Right Medicine at the Right Dose

SAN DIEGO, July 17, 2014 /PRNewswire/ -- Millennium Laboratories announced today that it has expanded its pharmacogenetic test (Millennium PGTSM) to include seven additional genes. The expanded test gives clinicians additional, objective information, based on patients' own genetics to help determine their potential response to a broad list of medications commonly prescribed across four key therapeutic areas, including pain, mental health, addiction and cardiovascular therapy.

Millennium PGT now analyzes clinically relevant genetic variants for 11 genes related to medication response to help clinicians individualize prescribing decisions. The Millennium Analysis of Patient Phenotype (MAPP®) Report provides clinicians with evidence based and clinically actionable information to support medication decisions for over 30 commonly prescribed medications across 14 medication classes. The MAPP Report also includes information for 20 medications with pharmacogenetic information or specific recommendations related to use in their U.S. Food and Drug Administration approved labels.  

"Millennium is providing clinical tools for improving care for all patients, and through investments in the newest technologies, we have delivered on that promise with our expanded PGT offering," said Chief Executive Officer, Brock Hardaway. "This milestone allows us to continue fulfilling a crucial need in health care, and offers additional tools that may help providers make more effective, individualized medication choices to get their patients on the path to wellness faster."

This saliva-based test helps clinicians determine, based on genetics, which medications are more likely to work for an individual patient, while helping them to avoid prescribing those more likely to cause adverse reactions. Millennium PGT helps health care providers minimize trial and error prescribing potentially shortening the time it takes for patients to feel better.

"It is very good to know it's the right drug, and it's very good to know that you're giving the right dose, and it's good to know that that patient is going to respond in the way you hope," said Dr. Manya Helman, family practice physician, Salem, Ore. "To be able to give the right drug, in the right dose, to right patient is exactly what our goal is."

In addition to the core offerings of CYP2D6, CYP2C19, CYP2B6, and UGT2B15, this expansion will significantly broaden Millennium's PGT menu to include CYP2C9, CYP3A4, CYP3A5, as well as VKORC1, COMT, MTHFR and OPRM1. Paired with PGT ConsultSM, a mobile application that provides evidence-based clinical decision support to health care providers, Millennium PGT is helping clinicians optimize patient care. 

About Millennium PGT
Millennium PGT is a laboratory developed pharmacogenetic test that analyzes clinically important genetic variations associated with how patients may respond to many commonly prescribed medicines. Millennium PGT is a saliva based test that provides clinicians with objective information that may help them individualize medication treatment decisions.

Millennium PGT is paired with the MAPP® Report, which provides clinicians with actionable information, based on a patient's own genetics, about their potential response to over 30 medications prescribed across four key therapeutic areas: pain, mental health, addiction and cardiovascular therapy. Together with PGT Consult, a mobile application that provides evidence-based clinical decision support, the combination of tools helps clinicians individualize medications to their patient's unique genetics, maximizing the opportunity for successful outcomes.

About Millennium Laboratories
Millennium Laboratories, a leader in the science of medication monitoring and pharmacogenetics, is transforming the way health care professionals monitor and manage their patients' medication therapy. Through the use of advanced technology, supported by research and education, Millennium helps practitioners personalize care for patients. Building on this strong foundation, Millennium aims to expand its impact by helping more people affected by chronic illnesses and dedicating itself to filling a crucial unmet need in health care. More information can be found at

Logo -
Logo -

SOURCE Millennium Laboratories, LLC
Copyright©2014 PR Newswire.
All rights reserved

Related biology news :

1. NJIT professor promotes building material of millennium: Autoclave aerated concrete
2. Millennium Laboratories Launches New Assay to Detect Use of Kratom
3. The millennium-old olive trees of the Iberian Peninsula are younger than expected
4. Breakthrough made at Max F. Perutz Laboratories
5. Nelson Laboratories to Offer Free Biocompatibility Consultations During BIOMEDevice San Jose
6. New report reviews science and engineering quality at national security laboratories
7. Shared Medical Resources, LLC files suit against Histologics, LLC, Womens Health Laboratories and Avero Diagnostics for Willful Patent Infringement
8. The Human Frontier Science Program selects new heads of start-up laboratories
9. FDA Grants Meridian Laboratories Pre-Ind Meeting for Captisol-Enabled Docetaxel in the Treatment of Cancer
10. 2012 ACMG Foundation/Signature Genomic Laboratories Travel Award winner announced
11. DigitalPersona Expands Secure Banking Solutions Portfolio with Software Acquisition
Post Your Comments:
(Date:10/12/2015)... , Oct. 9, 2015 Research and Markets ... Research, Inc,s new report "Biometrics: Market Shares, Strategies, ... --> --> The ... the Biometrics market segment. Research represents a selection from ... and cogent market materials, with selections made by the ...
(Date:10/8/2015)... Oct. 8, 2015 Synaptics Inc. (NASDAQ: ... solutions, announced today that it will report financial ... on Thursday, October 22, 2015, after the close ... conference call for analysts and investors at 2:00 ... may discuss forward-looking information. ...
(Date:10/6/2015)... 6, 2015 Track Group, Inc. (OTCQX: TRCK), ... has signed a contract with the Virginia Department of ... range of sentences under the Department,s oversight. ... "This contract with the Virginia DOC will expand our ... advances our position as a trusted leader in offender ...
Breaking Biology News(10 mins):
(Date:10/12/2015)... This report covers the global cell expansion ... applications, end-user markets and geographic segmentation. Forecasts are provided ... cell expansion market generated revenue of roughly $8.5 billion ... $9.7 billion in 2015 and $22.0 billion by 2020, ... from 2015 to 2020. This report provides: ...
(Date:10/12/2015)... FRANCISCO , October 12, 2015 ... USD 6.49 billion by 2022, according to a new report ... be attributed to rise in incidence of oncology diseases and ... market is expected to reach USD 6.49 billion by ... Inc. This growth in demand can be attributed to rise ...
(Date:10/12/2015)... CITY , Oct. 12, 2015 /PRNewswire/ - Aeterna ... specialty biopharmaceutical company engaged in developing and commercializing novel ... the departure of Dennis Turpin , the Company,s ... decision to close its Quebec City ... Chairman, President and Chief Executive Officer of the Company ...
(Date:10/12/2015)... , October 12, 2015 LabStyle ... Diabetes Management Solution, today announced its Medical Director, Dr. ... study at MobiHealth,s 5th EAI International Conference on ... healthcare through innovations in mobile and wireless technologies," the ... from October 14 - 16, 2015. The ...
Breaking Biology Technology: